1 citations
,
October 2020 in “Current Drug Discovery Technologies” The research found that compound 6, a newly created steroid, is more effective at inhibiting 5α-reductase (an enzyme) than current treatments, suggesting it could be a better option for treating urinary tract symptoms in men.
June 2010 in “Journal of Chemical Crystallography” The compound was successfully made and shows potential for treating prostate cancer.
May 2022 in “Current Enzyme Inhibition” Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.
3 citations
,
January 1992 in “Gynecological Endocrinology” 3α, 17β-androstanediol-glucuronide is not a useful marker for androgen excess but may help monitor certain treatments.
July 2012 in “Springer eBooks” The document concludes that proper diagnosis and treatment of nonscarring alopecias can improve quality of life and hair regrowth is possible as the hair follicle remains intact.
8 citations
,
June 2017 in “Steroids” New chemical compounds were made that effectively block an enzyme linked to prostate growth.
7 citations
,
August 2010 in “Medicinal Chemistry Research” Some synthesized compounds were more effective than Finasteride in reducing prostate cancer cell growth and androgen levels.
1 citations
,
January 2009 in “X-ray Structure Analysis Online” A new compound was made that might help treat diseases related to male hormones.
13 citations
,
July 2008 in “Biomedical Chromatography” The methods accurately measured brain androgens, showing most 5α-androstane-3α,17β-diol comes from outside the brain, while androsterone is both transported and made in the brain.
2 citations
,
October 2001 in “Analytical Sciences” A new compound that could treat various androgen-related conditions was created and analyzed.